Peking University, July 11, 2012: Peking University Clinical Research Institute (PUCRI) signed cooperation agreement last month with IMI’s program “PharmaTrain”, according to which the CCDRS (Chinese Course on Drug Development and Regulatory Sciences) held by PKU will become part of the program.

This event was the beginning of the future academic, cultural exchanges and cooperation between PUCRI and IMI staff and students to further improve their training level.

It’s also a symbol that after 3-year development, CCDRS’s course content, organizational management and teaching quality have been internationally recognized. This cooperation will further improve CCDRS on its degree of internationalization and teaching management level, and thus further develop China’s pharmaceutical industry.

Background Info:

IMI (The Innovative Medicines Initiative) is a campaign of the largest scale among governments, academic institutions and enterprises in Europe, which is organized by the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). It aims at doing research more quickly and developing better and safer medicines for the public. It provides capital for building platform for the communication among enterprises, academic fields and supervisors from governments to stimulate the innovation of medicines.

Written by: Bai Bing

Edited by: Arthars

Source: bynews (PKU Health Science Center)